Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants

Description

A comprehensive analysis of the impact of exogenous enteral DHA and ARA supplementation on lipid metabolism including the production of downstream derived mediators and how this impacts important biological pathways such as metabolism, inflammation, and organogenic factors.

Conditions

Premature

Study Overview

Study Details

Study overview

A comprehensive analysis of the impact of exogenous enteral DHA and ARA supplementation on lipid metabolism including the production of downstream derived mediators and how this impacts important biological pathways such as metabolism, inflammation, and organogenic factors.

Metabolic Mechanisms Induced by Enteral Docosahexaenoic Acid (DHA) and Arachidonic Acid (ARA) Supplementation in Preterm Infants

Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants

Condition
Premature
Intervention / Treatment

-

Contacts and Locations

Los Angeles

University of California, Los Angeles (UCLA), Los Angeles, California, United States, 90404

New Haven

Yale New Haven Hospital, New Haven, Connecticut, United States, 06511

Chicago

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States, 60611

Chicago

Northwestern University, Chicago, Illinois, United States, 60611

New York

Weill Cornell Medicine, New York, New York, United States, 10021

San Antonio

University Health System, San Antonio, Texas, United States, 78229

San Antonio

University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States, 78229

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * born between 25 0/7 and 29 6/7 weeks of gestation
  • * less than 48 hours of age at first lipid dose (The cohort is defined by gestational age rather than birth weight to avoid an over-represented sample of growth-restricted infants in birth weight defined cohorts.)
  • * serious congenital anomalies
  • * conditions at birth that will require surgery prior to discharge
  • * imminent death such that withdrawal of intensive care support is anticipated within the first 72 hours after birth

Ages Eligible for Study

to 36 Weeks

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

The University of Texas Health Science Center at San Antonio,

Cynthia Blanco, MD, MSCI-TS, PRINCIPAL_INVESTIGATOR, University of Texas Health Science Center San Antonio

Study Record Dates

2028-04